NCLEX-RN Pharmacology: The Complete Guide With High-Yield Drug Classes

NCLEX-RN pharmacology questions test whether the candidate can administer the right drug safely, monitor for the right side effects, and teach the patient appropriately. The exam is heavy on application: a vignette gives a patient scenario and asks which drug, which dose, which order to administer, what to teach, what to monitor, and what to do if a complication develops. Memorizing every brand name is a low-yield strategy — the high-yield strategy is mastering 50-60 representative drugs across 12 major classes, understanding the mechanism, knowing the boxed warnings, and applying nursing considerations consistently. The drug classes that appear most frequently on NCLEX are cardiovascular (especially anti-hypertensives and anti-arrhythmics), anticoagulants, diabetes medications, antibiotics, psychiatric drugs (SSRIs, antipsychotics, lithium), pain management (opioids, NSAIDs, acetaminophen), respiratory (bronchodilators, corticosteroids), and electrolyte/fluid agents. Mastery of these eight categories covers 80%+ of NCLEX pharm content.

ACE Inhibitors (lisinopril, enalapril, captopril). MOA: block angiotensin-converting enzyme, reducing angiotensin II and aldosterone. Effects: vasodilation, decreased preload/afterload, reduced cardiac remodeling. Adverse effects: dry cough (10-20% — hallmark NCLEX cue), hyperkalemia (especially with K-sparing diuretics or in CKD), angioedema (rare but life-threatening — facial/laryngeal swelling, switch class). Teaching: report cough, swelling. Monitor: BP, K+, BUN/creatinine. ARBs (losartan, valsartan, candesartan). MOA: block angiotensin II receptor directly. Use when ACE inhibitor not tolerated (no cough, less angioedema). Same hyperkalemia risk. Beta-blockers (metoprolol, atenolol, propranolol, carvedilol). MOA: block β1 (cardioselective: metoprolol, atenolol) or β1+β2 (non-selective: propranolol, nadolol). Effects: decreased HR, decreased contractility, decreased BP. Adverse: bronchospasm (β2 in non-selective), bradycardia, masked hypoglycemia symptoms in diabetics, fatigue. Hold parameters: typically hold if HR <60 or SBP <90. Never stop abruptly (rebound tachycardia, MI risk). Calcium channel blockers (amlodipine, nifedipine, diltiazem, verapamil). Two subclasses: dihydropyridines (amlodipine, nifedipine — vascular-selective, treat hypertension) vs non-dihydropyridines (diltiazem, verapamil — cardiac-selective, treat arrhythmias). Adverse: peripheral edema (dihydropyridines), constipation (verapamil), bradycardia (non-dihydropyridines). Thiazide diuretics (HCTZ, chlorthalidone). MOA: inhibit Na/Cl reabsorption in distal tubule. Effects: mild diuresis, BP reduction. Adverse: hypokalemia, hypomagnesemia, hyperglycemia, hyperuricemia (increases gout). Teaching: take in morning to avoid nighttime urination. Loop diuretics (furosemide, bumetanide, torsemide). MOA: inhibit Na/K/2Cl in loop of Henle. Effects: profound diuresis. Adverse: hypokalemia (severe — common cause of hospital admission), hypomagnesemia, ototoxicity (with rapid IV push), gout. Digoxin. MOA: inhibits Na/K-ATPase, increasing intracellular Ca and contractility. Used for CHF and atrial fibrillation rate control. Therapeutic range narrow: 0.5-2.0 ng/mL. Toxicity: nausea, anorexia, visual disturbances (yellow-green halos), arrhythmias. Hypokalemia INCREASES digoxin toxicity (a heavily-tested NCLEX point). Antidote: digoxin immune Fab (Digibind). Anti-arrhythmics (amiodarone, lidocaine, adenosine). Amiodarone has serious adverse effects: pulmonary fibrosis, hepatotoxicity, thyroid dysfunction, corneal microdeposits. Long half-life (months) means side effects persist after discontinuation.

Heparin (unfractionated). MOA: enhances antithrombin III, inhibits IIa and Xa. Monitoring: aPTT (target 1.5-2.5× control). Antidote: protamine sulfate (1 mg per 100 units heparin). Adverse: bleeding, heparin-induced thrombocytopenia (HIT — typically 5-10 days after start, platelets drop >50%, paradoxical thrombosis). Low-molecular-weight heparin (enoxaparin, dalteparin). MOA: inhibits Xa more than IIa. Subcutaneous administration; weight-based dosing. Less HIT than unfractionated. Anti-Xa monitoring rather than aPTT. Antidote: protamine (partial reversal). Warfarin. MOA: inhibits vitamin K epoxide reductase, depleting vitamin K-dependent factors II, VII, IX, X. Slow onset (3-5 days, since existing factors must clear). Monitoring: PT/INR (target 2-3 for most indications, 2.5-3.5 for mechanical valves). Antidote: vitamin K (slow, days), prothrombin complex concentrate or fresh-frozen plasma (fast, minutes-hours). Drug interactions massive: many antibiotics, NSAIDs, foods (vitamin K — green leafy vegetables — DECREASE INR; alcohol increases INR). Patient teaching: consistent vitamin K intake (not avoidance), no NSAIDs, alcohol limit. DOACs (direct oral anticoagulants): apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa). Inhibit Xa (apixaban, rivaroxaban) or IIa (dabigatran) directly. Advantages: no INR monitoring required, fewer drug interactions, fewer dietary restrictions. Disadvantages: shorter half-life means missed doses are higher-stakes, antidotes only recently available (idarucizumab for dabigatran, andexanet alfa for Xa inhibitors). Antiplatelets: aspirin (81 mg low-dose), clopidogrel (Plavix), prasugrel, ticagrelor. MOA: aspirin inhibits COX-1 (irreversible) → decreased TXA2; P2Y12 inhibitors (clopidogrel etc.) block platelet activation. Used for cardiovascular protection. Adverse: bleeding, GI ulceration (aspirin). Discontinue 5-7 days before surgery if possible (especially clopidogrel — irreversible inhibition lasts platelet lifespan).

Insulin types and timing (heavily tested): - Rapid-acting (lispro, aspart, glulisine): onset 15 min, peak 1-2 hr, duration 3-5 hr. Give immediately before meals. - Short-acting (regular insulin): onset 30 min, peak 2-4 hr, duration 5-8 hr. Give 30 min before meals. - Intermediate (NPH): onset 2 hr, peak 4-12 hr (variable), duration 12-18 hr. Cloudy. - Long-acting (glargine, detemir): onset 1-2 hr, no peak, duration 24 hr. Give same time daily. - Ultra-long (degludec): duration 42 hr. NCLEX favorite: timing of peak action determines hypoglycemia risk window. Patient on NPH at 8 AM should be monitored for hypoglycemia at noon-8 PM (peak 4-12 hr). Patient on long-acting glargine has no peak, so hypoglycemia risk is more uniform. Sliding scale: insulin doses adjusted based on blood glucose readings. Type 1 diabetics on basal-bolus regimens; type 2 may use basal alone. Insulin administration: rotate sites (abdomen fastest absorption, thigh/arm slower), do NOT massage after injection (changes absorption rate). Metformin. MOA: decreases hepatic glucose production. Adverse: GI upset (most common), lactic acidosis (rare but serious, especially in renal impairment). Hold for contrast studies (kidneys), restart 48 hr after if creatinine stable. Sulfonylureas (glipizide, glyburide). MOA: stimulate pancreatic beta cell insulin release. Adverse: hypoglycemia (more than metformin), weight gain. GLP-1 agonists (semaglutide, liraglutide). MOA: enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying. Adverse: nausea (very common), weight loss (often desired), pancreatitis (rare). SGLT2 inhibitors (empagliflozin, dapagliflozin). MOA: inhibit glucose reabsorption in proximal tubule. Adverse: UTIs, genital infections, euglycemic DKA (rare). DKA management: IV fluids first (NS), insulin drip (regular insulin IV), correct potassium BEFORE insulin (insulin drives K into cells, dropping serum K dangerously). Bicarbonate only for severe acidosis (pH <6.9).

Penicillins (amoxicillin, amoxicillin-clavulanate, piperacillin-tazobactam). MOA: cell wall synthesis inhibitor. Adverse: allergy (most common), C. diff. Penicillin allergy: 1-3% true allergy; may have cross-reactivity with cephalosporins (low — ~1%). Cephalosporins (5 generations). 1st (cefazolin): gram+; surgical prophylaxis. 3rd (ceftriaxone): broad-spectrum; meningitis treatment. 4th (cefepime): pseudomonas coverage. 5th (ceftaroline): MRSA coverage. Aminoglycosides (gentamicin, tobramycin, amikacin). MOA: protein synthesis inhibitor. Adverse: ototoxicity (irreversible — heavily tested NCLEX), nephrotoxicity. Monitor peak and trough levels; trough most important for toxicity. Renal dose adjustment. Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin). MOA: DNA gyrase inhibitor. Adverse: tendon rupture (especially Achilles, especially in elderly on corticosteroids — boxed warning), QT prolongation, photosensitivity. Avoid in pregnancy and pediatrics (cartilage damage in animal studies). Macrolides (azithromycin, erythromycin, clarithromycin). MOA: protein synthesis. Adverse: GI (severe with erythromycin), QT prolongation, hepatotoxicity. Many drug interactions (CYP3A4 inhibition). Vancomycin. MOA: cell wall synthesis. Used for MRSA, C. diff (oral, not absorbed). Adverse: red man syndrome (NOT allergy — histamine release from rapid infusion; slow infusion or pre-treat with antihistamine), nephrotoxicity, ototoxicity. Monitor trough levels. Metronidazole (Flagyl). Adverse: disulfiram-like reaction with alcohol (severe nausea, vomiting, flushing — patient teaching critical), neurotoxicity with prolonged use. Antibiotic-associated diarrhea: many antibiotics disrupt normal gut flora → C. difficile overgrowth. Treatment: oral vancomycin or fidaxomicin. Severe case: pseudomembranous colitis, toxic megacolon. Hand washing with soap (not alcohol — alcohol does not kill C. diff spores) is the prevention strategy.

SSRIs (fluoxetine, sertraline, citalopram, escitalopram). MOA: block serotonin reuptake. Adverse: GI upset, sexual dysfunction, increased suicidal ideation in young adults (boxed warning). Onset: 4-6 weeks for full antidepressant effect. Patient teaching: do not stop abruptly (discontinuation syndrome), takes weeks to work. TCAs (amitriptyline, nortriptyline). Adverse: anticholinergic (dry mouth, urinary retention, constipation, blurred vision), sedation, orthostatic hypotension, cardiac toxicity in overdose (sodium channel blockade). MAOIs (phenelzine). Adverse: hypertensive crisis with tyramine-containing foods (aged cheese, cured meats, red wine, fermented foods). Patient teaching extensive; avoid 14 days washout when switching. Lithium. Therapeutic range narrow: 0.6-1.2 mEq/L. Adverse: tremor, polyuria, weight gain, hypothyroidism. Toxicity: >1.5 mEq/L (nausea, ataxia, slurred speech), >2.5 (seizures, death). Drug interactions with NSAIDs, ACE inhibitors, thiazides (raise lithium levels). Sodium intake matters: low Na = high Li retention. Monitoring: serum levels, TSH, BUN/Cr. Antipsychotics (haloperidol, risperidone, olanzapine, clozapine). Adverse: extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism, tardive dyskinesia), neuroleptic malignant syndrome (NMS — fever, rigidity, autonomic instability — medical emergency), metabolic syndrome (weight gain, diabetes), QT prolongation. Clozapine: agranulocytosis (weekly CBC monitoring required). Opioids (morphine, oxycodone, hydromorphone, fentanyl). Adverse: respiratory depression (priority concern; antidote naloxone), constipation (always combat — start stool softener with opioid), nausea, sedation, dependence/tolerance. Pediatric and elderly: more sensitive — start lower doses. Naloxone: short half-life (60-90 min) → may need repeat doses for long-acting opioid. NSAIDs (ibuprofen, naproxen, ketorolac). Adverse: GI ulceration, kidney injury (especially in dehydration or CHF), increased CV events. Avoid in 3rd trimester pregnancy (premature ductus closure). Acetaminophen. Adverse: hepatotoxicity at >4 g/day (3 g if alcohol). Antidote for overdose: N-acetylcysteine (NAC). Corticosteroids (prednisone, methylprednisolone). Adverse: hyperglycemia, immunosuppression, osteoporosis, mood changes, adrenal suppression on chronic use. Never stop abruptly after >2 weeks of therapy — taper to avoid adrenal crisis.

Five rights of medication administration (NCLEX foundational): right patient, right drug, right dose, right route, right time. Some sources add three more: right documentation, right reason, right response. Verification at the bedside: identify the patient using two identifiers (name + DOB, name + medical record number) — never rely on room number alone. Read the medication label three times: when retrieving, when preparing, before administering. High-alert medications (require double-check): insulin, heparin, anticoagulants, opioids, chemotherapy, concentrated electrolytes (KCl never push). Many institutions require two RN verification. Route-specific considerations: - Oral: can the patient swallow? NPO orders override. Crush only those marked safe to crush. - IV push: rate matters (rapid push = adverse effects; vancomycin red man, furosemide ototoxicity) - Subcutaneous: rotate sites; do not aspirate insulin or heparin - IM: large muscle (deltoid, vastus lateralis, ventrogluteal); aspirate before injection (some still teach, others don't); avoid Z-track for irritating medications - IV piggyback: check compatibility with primary IV; rate per pump Black box warnings: highest-level FDA warning. NCLEX expects recognition of major black box warnings (suicidal ideation in SSRIs young adults; tendon rupture with fluoroquinolones; tardive dyskinesia with antipsychotics; agranulocytosis with clozapine). Patient teaching priorities by class: anticoagulants (signs of bleeding, fall prevention, drug/food interactions); diabetes meds (hypoglycemia signs, sick-day rules); antibiotics (complete the course, GI upset prevention with probiotics); psych meds (do not stop abruptly, takes weeks to work); opioids (constipation prevention, respiratory depression warning).

NCLEX pharmacology is the most-failed content area for many nursing students because of the volume and the application focus. Snap a photo of any pharmacology problem and NurseIQ identifies the drug class, walks through mechanism and adverse effects, applies nursing considerations to the scenario, and produces the priority intervention or teaching point. For drug calculations (mL/hr from mg/min, mEq conversions, IV drip rates), NurseIQ shows the dimensional analysis step by step. This content is for educational purposes only and supports nursing student learning.